BACKGROUND: Fibrolamellar carcinoma is a rare and poorly understood malignancy that affects the young in the absence of underlying liver disease. Despite reported small review series, the literature lacks large retrospective studies that may help in understanding this disease. METHODS: Medical record review was undertaken for all patients histopathologically diagnosed with fibrolamellar carcinoma, seen at Memorial Sloan-Kettering Cancer Center, the University of California San Francisco, and Johns Hopkins Hospital from 1986 to 2011. Demographic, clinical, pathologic, and treatment data were recorded. Overall survival was estimated by using Kaplan-Meier methods. The impact of different clinicopathologic variables on survival was assessed with Cox regression models. RESULTS: Ninety-five patients were identified. Median age was 22 years, 86% were Caucasian, and 50% presented with stage IV disease. There were more females than males (58% vs. 42%). Seventy-seven percent of the patients underwent surgical resection and/or liver transplantation; of these 31.5% received perioperative therapy. Patients with unresectable disease, including 8 patients treated in clinical trials, were treated with chemotherapy, occasionally given with interferon or biologic agents. Ten patients received sorafenib, and 7 received best supportive care. Median survival was 6.7 years. Factors significantly associated with poor survival were female sex, advanced stage, lymph node metastases, macrovascular invasion, and unresectable disease. CONCLUSIONS: The clinicopathologic characteristics and survival outcomes from this dataset are consistent with those reported in the literature. Surgical resection and disease extent were confirmed as important predictors of survival. The possibility of a negative association between female sex and prognosis could represent a clue as to future therapeutic strategies.
BACKGROUND:Fibrolamellar carcinoma is a rare and poorly understood malignancy that affects the young in the absence of underlying liver disease. Despite reported small review series, the literature lacks large retrospective studies that may help in understanding this disease. METHODS: Medical record review was undertaken for all patients histopathologically diagnosed with fibrolamellar carcinoma, seen at Memorial Sloan-Kettering Cancer Center, the University of California San Francisco, and Johns Hopkins Hospital from 1986 to 2011. Demographic, clinical, pathologic, and treatment data were recorded. Overall survival was estimated by using Kaplan-Meier methods. The impact of different clinicopathologic variables on survival was assessed with Cox regression models. RESULTS: Ninety-five patients were identified. Median age was 22 years, 86% were Caucasian, and 50% presented with stage IV disease. There were more females than males (58% vs. 42%). Seventy-seven percent of the patients underwent surgical resection and/or liver transplantation; of these 31.5% received perioperative therapy. Patients with unresectable disease, including 8 patients treated in clinical trials, were treated with chemotherapy, occasionally given with interferon or biologic agents. Ten patients received sorafenib, and 7 received best supportive care. Median survival was 6.7 years. Factors significantly associated with poor survival were female sex, advanced stage, lymph node metastases, macrovascular invasion, and unresectable disease. CONCLUSIONS: The clinicopathologic characteristics and survival outcomes from this dataset are consistent with those reported in the literature. Surgical resection and disease extent were confirmed as important predictors of survival. The possibility of a negative association between female sex and prognosis could represent a clue as to future therapeutic strategies.
Authors: A D Pinna; S Iwatsuki; R G Lee; S Todo; J R Madariaga; J W Marsh; A Casavilla; I Dvorchik; J J Fung; T E Starzl Journal: Hepatology Date: 1997-10 Impact factor: 17.425
Authors: James D McDonald; Shreya Gupta; Mackenzie L Shindorf; Lauren A Gamble; Samantha M Ruff; Justin Drake; Theo Heller; Jim Y Wan; Paxton V Dickson; Evan S Glazer; Jeremy L Davis; Jeremiah L Deneve; Jonathan M Hernandez Journal: Ann Surg Oncol Date: 2020-01-10 Impact factor: 5.344
Authors: Imane El Dika; Anita S Bowman; Michael F Berger; Marinela Capanu; Joanne F Chou; Ryma Benayed; Ahmet Zehir; Jinru Shia; Eileen M O'Reilly; David S Klimstra; David B Solit; Ghassan K Abou-Alfa Journal: Cancer Date: 2020-07-14 Impact factor: 6.860
Authors: Elana P Simon; Catherine A Freije; Benjamin A Farber; Gadi Lalazar; David G Darcy; Joshua N Honeyman; Rachel Chiaroni-Clarke; Brian D Dill; Henrik Molina; Umesh K Bhanot; Michael P La Quaglia; Brad R Rosenberg; Sanford M Simon Journal: Proc Natl Acad Sci U S A Date: 2015-10-21 Impact factor: 11.205
Authors: Ahmed O Kaseb; Mohamed Shama; Ibrahim Halil Sahin; Ajay Nooka; Hesham M Hassabo; Jean-Nicolas Vauthey; Thomas Aloia; James L Abbruzzese; Ishwaria M Subbiah; Filip Janku; Steven Curley; Manal M Hassan Journal: Oncology Date: 2013-09-19 Impact factor: 2.935
Authors: Joshua N Honeyman; Elana P Simon; Nicolas Robine; Rachel Chiaroni-Clarke; David G Darcy; Irene Isabel P Lim; Caroline E Gleason; Jennifer M Murphy; Brad R Rosenberg; Lydia Teegan; Constantin N Takacs; Sergio Botero; Rachel Belote; Soren Germer; Anne-Katrin Emde; Vladimir Vacic; Umesh Bhanot; Michael P LaQuaglia; Sanford M Simon Journal: Science Date: 2014-02-28 Impact factor: 47.728
Authors: Suguru Yamashita; Jean-Nicolas Vauthey; Ahmed O Kaseb; Thomas A Aloia; Claudius Conrad; Manal M Hassan; Guillaume Passot; Kanwal P Raghav; Mohamed A Shama; Yun Shin Chun Journal: J Gastrointest Surg Date: 2016-07-25 Impact factor: 3.452
Authors: Ghassan K Abou-Alfa; Robert Mayer; Alan P Venook; Allison F O'Neill; Muhammad S Beg; Michael LaQuaglia; Peter T Kingham; Rachel Kobos; Olca Basturk; Cameron Brennan; Adam Yopp; James J Harding; Stephen Leong; John Crown; Emir Hoti; Gregory Leonard; Michele Ly; Mikaela Bradley; Emily Valentino; David Markowitz; Alexander Zukiwski; Ken Ren; John D Gordan Journal: Oncologist Date: 2020-03-10